Chronic Obstructive Pulmonary Disease (COPD) Drugs
Due to the unhealthy lifestyle
among people in consumerist cultures, pollution, and various reasons, the
number of people suffering from respiratory disorders and chronic diseases is
rising. Among these, a common one is a chronic obstructive pulmonary disease
(COPD). This obstructive lung disease characterized by long-term breathing
problems and poor airflow. When a disease becomes common, and the number of
people suffering from it goes up, so does the market offering treatment for it.
The major factor driving the growth of market COPD treatment is the increasing
number of adult smokers. Due to environmental pollution, the number of rapidly
growing asthma patients is increasing the growth of the COPD market.
Market Research Future (MRFR) has
published a research report about the global Chronic Obstructive Pulmonary Disease (COPD) Drugs that measures huge elevation in this market
between 2016 and 2022. This report provides a detailed analysis of market
structure with the forecast for next years and provides insights into factors
affecting the market growth. Analyzing the market on the basis of various
factors, it evaluates the market with current market size and future potential
regarding growth. Profiling various key players in the market, the report
discusses their activities and observes competitive developments like joint
ventures, mergers and acquisitions, new product developments, strategic alliances,
and research and developments (R & D).
The global Chronic Obstructive
Pulmonary Disease (COPD) Drugs has been segmented into medicines, treatments,
types, and lastly region. On the basis of medicines, this market has been
segmented into antibiotics, bronchodilators, combination inhalers, inhaled
steroids, oral steroids, phosphodiesterase-4 inhibitors, and theophylline.
Antibiotics are useful for fighting bacterial infections. Bronchodilators are
medications that open (dilate) the airways (bronchial tubes) of the lung by
relaxing bronchial muscles. They allow people with difficulty in breathing to
breathe better. A combination inhaler combines two kinds of medicine in one
device. Usually, in a combination inhaler, one medicine is corticosteroid while
the other is a bronchodilator. Advair Diskus, Breo, Dulera, and Symbicort are
some examples of combination inhalers. Some examples of inhaled steroids
include Arnuity Ellipta, Flovent, Pulmicort, Qvar, and Symbicort are some
examples of inhaled steroids. Oral steroids are the non-narcotic type of
powerful prescription medication. Commonly called as a PDE4 inhibitor,
phosphodiesterase type 4 inhibitor, is a drug used to block the degradative
action of phosphodiesterase 4 (PDE4).
The treatment-based segmentation
of market comprises of oxygen therapy, lung transplant, bullectomy and others.
Bullectomy is the surgical process for the removal of a bulla, which is a
dilated air space in the lung parenchyma. A bulla measures more than 1 cm.
Bulla that occupies more than 30% of the hemithorax is called giant bulla.
Bulla is the most common cause of COPD. In oxygen therapy, oxygen is used for
medical treatment. Lung transplant is a medical process where a permanently
damaged lung of a patient is removed, and a healthy lung from another person is
planted into the body of the patient. By types, the global COPD market has been
segmented into chronic bronchitis and emphysema. Chronic Bronchitis (CB) is
defined as a chronic cough and sputum production for at least 3 months a year
for 2 consecutive years. Emphysema is a lung condition that causes shortness of
breath.
The regional segmentation of
global Chronic Obstructive Pulmonary Disease (COPD) Drugs covers The Americas
(North America & South Americas), Europe, Asia Pacific, and Middle East
& Africa (MEA). Among the Americas, North America is the bigger market for
COPD, than South America due to advanced medical facilities and more investment
in this region, the biggest local markets are the United States of America (USA)
and Canada. North America is the largest market among all regional markets.
Due to the reasons same as the
Americas, Western Europe is the bigger market, than Eastern Europe. Although
the market in whole Europe is decent and steady in Western Europe, the cream of
Europe market in France, Germany, Italy, Spain, and the United Kingdom (UK).
Europe is the second largest market for COPD.
In the Asia Pacific region, the
market is growing due to the high density of population and improving medical
facilities in some countries of this region. During the forecast period, Asia
Pacific is expected to be the fastest growing market for COPD. The biggest
markets in the Asia Pacific are Australia, China, India, Japan, and South
Korea, followed by the rest of the Asia Pacific. In the MEA region, the market
is small due to poor or limited infrastructure and less investment in health
care. However, due to hookah smoking, the number of people suffering from COPD
is sizable. In this region, the biggest markets are Kuwait, Oman, Saudi Arabia,
United Arab Emirates (UAE) and Qatar.
Access Report @ https://www.marketresearchfuture.com/reports/chronic-obstructive-pulmonary-disease-copd-market-1612
Key Players
The key players in global COPD
market are Abbott (USA), AstraZeneca (UK), Dr. Reddy’s Laboratories Ltd
(India), F. Hoffmann-La Roche Ltd (Switzerland), GSK (UK), Merck (USA),
Novartis AG (Switzerland), and Pfizer Inc (USA).
No comments:
Post a Comment